Test of two targeted drugs for tumors with BRAF V600E
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor with a BRAF V600E mutation confirmed by a local lab test
- You have at least one measurable tumor spot on scans (as judged by the trial team using RECIST v1.1)
- You have not previously taken dabrafenib and/or trametinib for this cancer (past use more than 1 year ago for other cancers may still be allowed)
- You can provide scan images for an additional central review
- Your cancer type is not melanoma, lung cancer (NSCLC), thyroid cancer (ATC), bile duct cancer (BTC), glioma, or colon/rectal cancer (CRC)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
This Phase 2 trial tests a targeted treatment for adults with papillary craniopharyngioma that has a specific BRAF change (V600E). It may help shrink or control the tumor, especially when surgery is not expected to remove it safely.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
Hear when a new Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.